Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
ASCO 2026
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500).
The ASCO Post Staff
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
The ASCO Post Staff
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic pancreatic adenocarcinoma (Abstract LBA5).
The ASCO Post Staff
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); BRUIN CLL-314 is comparing pirtobrutinib to ibrutinib in the same patient population (Abstract 7044).